Phase III Randomised, Double Blind, Placebo Controlled Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients With a Complete or Partial Response Following Platinum Based Chemotherapy
Latest Information Update: 08 Jul 2024
At a glance
- Drugs Olaparib (Primary)
- Indications Carcinoma; Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Registrational; Therapeutic Use
- Acronyms OSTRIA 2; SOLO2; SOLO2/ENGOT-Ov21
- Sponsors AstraZeneca
- 15 Jan 2024 Planned End Date changed from 29 Dec 2023 to 31 Dec 2024.
- 24 Dec 2022 This trial has been completed in Poland, according to European Clinical Trials Database record.
- 22 Dec 2022 Planned End Date changed from 30 Dec 2022 to 29 Dec 2023.